Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 5/20 | 0.59 |
| ▸ | SLC1A2 | P43004 | 3/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.48 |
| ▸ | GABRR2 | P28476 | 1/20 | 0.48 |
| ▸ | PEPD | P12955 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7150608 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL352246 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL2135258 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL20346208 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL6938207 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| SCHEMBL339332 | 1.00 | GABRR1 (0.59) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8452138 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8942934 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8942927 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD | |
| Hydrochloric Acid SCHEMBL8452135 | 0.96 | GABRR1 (0.56) | GABRR1SLC1A2SLC1A1GABRR2PEPD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 166 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11453635-B2 | Method of making cyclobutane-1, 2-diacids degradable building blocks for materials | UNIVERSITY OF NORTH DAKOTA (US) | 2022-09-27 | — | — | US | claimed |
| US-20210347718-A1 | METHOD OF MAKING CYCLOBUTANE-1, 2-DIACIDS DEGRADABLE BUILDING BLOCKS FOR MATERIALS | UNIVERSITY OF NORTH DAKOTA (US) | 2021-11-11 | — | — | US | claimed |
| CN-108135877-B | Pharmaceutical co-crystals and uses thereof | 新纳特产品公司 | 2021-04-13 | — | — | CN | claimed |
| EP-3297624-B1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | SYN NAT PRODUCTS ENTPR LLC (US) | 2021-03-03 | — | — | EP | claimed |
| US-10751318-B2 | Pharmaceutical co-crystal and use thereof | Syn-Nat Products Enterprise LLC (US) | 2020-08-25 | — | — | US | claimed |
| CN-106367755-B | Etchant composition, method of manufacturing array substrate for liquid crystal display device using the same, and array substrate | 东友精细化工有限公司 | 2019-12-17 | — | — | CN | claimed |
| US-20180289662-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | SYN NAT PRODUCTS ENTPR LLC (US) | 2018-10-11 | — | — | US | claimed |
| EP-3297624-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | Syn-Nat Products Enterprise LLC (US) | 2018-03-28 | — | — | EP | claimed |
| WO-2016187191-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | Medoc Pharmaceutical Co., Ltd. (CN) | 2016-11-24 | — | — | WO | claimed |
| US-7880026-B2 | preparing a reactant solution containing metal organic framework (MOF) precursors comprise Zn(NO3)2*6H2O and 4,4',4'',4'''-(21H,23H-porphine-5-10-15-20-tetrayl)tetrakis(benzoic acid), the reactant solution includes diethylformamide solvent, exposing to microwave to produce Zn-MOF crystal | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-02-01 | — | — | US | claimed |
| WO-2010100199-A1 | FLUCONAZOLE CARBOXYLIC ESTER DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS | SEPS PHARMA N.V. (BE) | 2010-09-10 | — | — | WO | claimed |
| US-20090131643-A1 | Rapid metal organic framework molecule synthesis method | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2009-05-21 | — | — | US | claimed |
| EP-1948353-A2 | HIGH GAIN SELECTIVE PRECONCENTRATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-07-30 | — | — | EP | claimed |
| WO-2008057140-A2 | RAPID METAL ORGANIC FRAMEWORK MOLECULE SYNTHESIS METHOD | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-05-15 | — | — | WO | claimed |
| WO-2007044473-A2 | HIGH GAIN SELECTIVE PRECONCENTRATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-19 | — | — | WO | claimed |
| CN-2651997-Y | Microairgap overvoltage protector | KANGMUXUN ELECTROMAGNETIC PROT (CN) | 2004-10-27 | — | — | CN | claimed |
| EP-0543264-B1 | Rewritable thermosensitive recording medium | TOPPAN PRINTING CO LTD (JP) | 1995-05-03 | — | — | EP | claimed |
| US-5278129-A | Low molecular weight alicyclic dicarboxylic acid | TOPPAN PRINTING CO., LTD. (JP) | 1994-01-11 | — | — | US | claimed |
| EP-0543264-A1 | Rewritable thermosensitive recording medium | Toppan Printing Co., Ltd. (JP) | 1993-05-26 | — | — | EP | claimed |
| CN-122010757-A | Process for preparing trans-cyclobutane-1, 2-dicarboxamide | 海南长安国际制药有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-12104012-B2 | Cyclobutane-containing thermally cleavable polymers | UNIVERSITY OF NORTH DAKOTA (US) | 2024-10-01 | — | — | US | disclosed |
| CN-116854745-A | Pharmaceutical co-crystal composition and use thereof | 新纳特产品公司 | 2023-10-10 | — | — | CN | disclosed |
| US-11685757-B2 | Pharmaceutical co-crystal composition and use thereof | Syn-Nat Products Enterprise LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685757-B2 | Pharmaceutical co-crystal composition and use thereof | Syn-Nat Products Enterprise LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11685757-B2 | Pharmaceutical co-crystal composition and use thereof | Syn-Nat Products Enterprise LLC (US) | 2023-06-27 | — | — | US | disclosed |
| US-11655360-B2 | Gas-barrier resin composition and use thereof | SHOWA DENKO K.K. (JP) | 2023-05-23 | — | — | US | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11453635-B2 | Method of making cyclobutane-1, 2-diacids degradable building blocks for materials | UNIVERSITY OF NORTH DAKOTA (US) | 2022-09-27 | — | — | US | disclosed |
| US-11453635-B2 | Method of making cyclobutane-1, 2-diacids degradable building blocks for materials | UNIVERSITY OF NORTH DAKOTA (US) | 2022-09-27 | — | — | US | disclosed |
| CN-110799600-B | Gas barrier resin composition and use thereof | 昭和电工株式会社 | 2022-06-21 | — | — | CN | disclosed |
| US-20210363294-A1 | CYCLOBUTANE-CONTAINING THERMALLY CLEAVABLE POLYMERS | UNIVERSITY OF NORTH DAKOTA (US) | 2021-11-25 | — | — | US | disclosed |
| US-20210347718-A1 | METHOD OF MAKING CYCLOBUTANE-1, 2-DIACIDS DEGRADABLE BUILDING BLOCKS FOR MATERIALS | UNIVERSITY OF NORTH DAKOTA (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210347718-A1 | METHOD OF MAKING CYCLOBUTANE-1, 2-DIACIDS DEGRADABLE BUILDING BLOCKS FOR MATERIALS | UNIVERSITY OF NORTH DAKOTA (US) | 2021-11-11 | — | — | US | disclosed |
| US-20210147669-A1 | GAS-BARRIER RESIN COMPOSITION AND USE THEREOF | SHOWA DENKO K.K. (JP) | 2021-05-20 | — | — | US | disclosed |
| CN-108135877-B | Pharmaceutical co-crystals and uses thereof | 新纳特产品公司 | 2021-04-13 | — | — | CN | disclosed |
| CN-108135877-B | Pharmaceutical co-crystals and uses thereof | 新纳特产品公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20210094979-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | Syn-Nat Products Enterprise LLC | 2021-04-01 | — | — | US | disclosed |
| US-20210094979-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | Syn-Nat Products Enterprise LLC | 2021-04-01 | — | — | US | disclosed |
| EP-3297624-B1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | SYN NAT PRODUCTS ENTPR LLC (US) | 2021-03-03 | — | — | EP | disclosed |
| US-10751318-B2 | Pharmaceutical co-crystal and use thereof | Syn-Nat Products Enterprise LLC (US) | 2020-08-25 | — | — | US | disclosed |
| US-10751318-B2 | Pharmaceutical co-crystal and use thereof | Syn-Nat Products Enterprise LLC (US) | 2020-08-25 | — | — | US | disclosed |
| WO-2020117519-A1 | METHOD OF MAKING CYCLOBUTANE-1, 2-DIACIDS DEGRADABLE BUILDING BLOCKS FOR MATERIALS | THE UNIVERSITY OF NORTH DAKOTA (US) | 2020-06-11 | — | — | WO | disclosed |
| WO-2020117517-A1 | CYCLOBUTANE-CONTAINING THERMALLY CLEAVABLE POLYMERS | THE UNIVERSITY OF NORTH DAKOTA (US) | 2020-06-11 | — | — | WO | disclosed |
| EP-3660105-A1 | GAS-BARRIER RESIN COMPOSITION AND USE THEREOF | Showa Denko K.K. (JP) | 2020-06-03 | — | — | EP | disclosed |
| CN-110799600-A | Gas barrier resin composition and use thereof | 昭和电工株式会社 | 2020-02-14 | — | — | CN | disclosed |
| CN-106367755-B | Etchant composition, method of manufacturing array substrate for liquid crystal display device using the same, and array substrate | 东友精细化工有限公司 | 2019-12-17 | — | — | CN | disclosed |
| US-10428099-B2 | Pharmaceutical co-crystal composition and use thereof | Syn-Nat Products Enterprise LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428099-B2 | Pharmaceutical co-crystal composition and use thereof | Syn-Nat Products Enterprise LLC (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20180289662-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | SYN NAT PRODUCTS ENTPR LLC (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180289662-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | SYN NAT PRODUCTS ENTPR LLC (US) | 2018-10-11 | — | — | US | disclosed |
| US-20180186822-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | Syn-Nat Products Enterprise LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180186822-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | Syn-Nat Products Enterprise LLC | 2018-07-05 | — | — | US | disclosed |
| US-20180186822-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | Syn-Nat Products Enterprise LLC | 2018-07-05 | — | — | US | disclosed |
| EP-3297624-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | Syn-Nat Products Enterprise LLC (US) | 2018-03-28 | — | — | EP | disclosed |
| EP-3297624-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | Syn-Nat Products Enterprise LLC (US) | 2018-03-28 | — | — | EP | disclosed |
| WO-2017218714-A1 | GENETICALLY MODIFIED CELLS, TISSUES, AND ORGANS FOR TREATING DISEASE | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2017-12-21 | — | — | WO | disclosed |
| EP-2603511-B1 | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2017-03-15 | — | — | EP | disclosed |
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2017-01-19 | — | — | US | disclosed |
| WO-2016187191-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | Medoc Pharmaceutical Co., Ltd. (CN) | 2016-11-24 | — | — | WO | disclosed |
| WO-2016187191-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | Medoc Pharmaceutical Co., Ltd. (CN) | 2016-11-24 | — | — | WO | disclosed |
| US-9492496-B2 | Aminothiazoles and their uses | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| US-9492496-B2 | Aminothiazoles and their uses | NOVARTIS AG (CH) | 2016-11-15 | — | — | US | disclosed |
| EP-3053924-A1 | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D]PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-08-10 | — | — | EP | disclosed |
| US-9328120-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| US-9328120-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2016-05-03 | — | — | US | disclosed |
| EP-2675806-B1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INT (DE) | 2015-08-05 | — | — | EP | disclosed |
| EP-2675807-B1 | 6-CYCLOBUTYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-04-22 | — | — | EP | disclosed |
| EP-2832720-A1 | 1,2-disubstituted cyclobutyl compounds | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2015-02-04 | — | — | EP | disclosed |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-22 | — | — | US | disclosed |
| US-8912201-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-8912201-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-16 | — | — | US | disclosed |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-8809345-B2 | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of CNS disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| EP-2675806-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | Boehringer Ingelheim International GmbH (DE) | 2013-12-25 | — | — | EP | disclosed |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2013-09-05 | — | — | US | disclosed |
| US-8445572-B2 | Rubber composition | THE YOKOHAMA RUBBER CO., LTD. (JP) | 2013-05-21 | — | — | US | disclosed |
| WO-2012110440-A9 | 6 - CYCLOBUTYL - 1, 5 - DIHYDRO - PYRAZOLO [3, 4-D] PYRIMIDIN- 4 - ONE DERIVATIVES THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-14 | — | — | WO | disclosed |
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040955-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-02-14 | — | — | US | disclosed |
| WO-2012110441-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-23 | — | — | WO | disclosed |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-08-09 | — | — | US | disclosed |
| US-8123834-B2 | High gain selective metal organic framework preconcentrators | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2012-02-28 | — | — | US | disclosed |
| WO-2012020022-A1 | 6-CYCLOALKYL-1, 5-DIHYDRO-PYRAZOLO [3, 4-D] PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE AS PDE9A INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-16 | — | — | WO | disclosed |
| US-7880026-B2 | preparing a reactant solution containing metal organic framework (MOF) precursors comprise Zn(NO3)2*6H2O and 4,4',4'',4'''-(21H,23H-porphine-5-10-15-20-tetrayl)tetrakis(benzoic acid), the reactant solution includes diethylformamide solvent, exposing to microwave to produce Zn-MOF crystal | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2010100199-A1 | FLUCONAZOLE CARBOXYLIC ESTER DERIVATIVES, SYNTHESIS, AND USE IN LONG ACTING FORMULATIONS | SEPS PHARMA N.V. (BE) | 2010-09-10 | — | — | WO | disclosed |
| US-20100222478-A1 | RUBBER COMPOSITION | THE YOKOHAMA RUBBER CO., LTD (JP) | 2010-09-02 | — | — | US | disclosed |
| US-20100132547-A1 | HIGH GAIN SELECTIVE METAL ORGANIC FRAMEWORK PRECONCENTRATORS | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2010-06-03 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| US-20090306134-A1 | Muscarinic receptor antagonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2009-12-10 | — | — | US | disclosed |
| WO-2009074605-A1 | AMINOTHIAZOLES AND THEIR USES | NOVARTIS AG (CH) | 2009-06-18 | — | — | WO | disclosed |
| US-20090131643-A1 | Rapid metal organic framework molecule synthesis method | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS, THE | 2009-05-21 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-20090111737-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2009-04-30 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456203-B2 | Muscarinic receptor antagonists | THERAVANCE, INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-10-30 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| US-7427639-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-09-23 | — | — | US | disclosed |
| EP-1948353-A2 | HIGH GAIN SELECTIVE PRECONCENTRATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-07-30 | — | — | EP | disclosed |
| WO-2008057140-A2 | RAPID METAL ORGANIC FRAMEWORK MOLECULE SYNTHESIS METHOD | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070196859-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-08-23 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2007-08-02 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070154948-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-07-05 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-20070134729-A1 | Novel antibacterial agents | THERAVANCE BIOPHARMA ANTIBIOTICS IP, LLC | 2007-06-14 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7217738-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-15 | — | — | US | disclosed |
| US-7211695-B2 | β2-adrenergic receptor agonists | THERAVANCE, INC. (US) | 2007-05-01 | — | — | US | disclosed |
| WO-2007044473-A2 | HIGH GAIN SELECTIVE PRECONCENTRATORS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2007-04-19 | — | — | WO | disclosed |
| EP-1506955-B1 | Bicyclic amino acids as pharmaceuticals agents | WARNER LAMBERT CO (US) | 2007-03-28 | — | — | EP | disclosed |
| US-7189747-B2 | Method of treating noninflammatory cartilage damage | WARNER-LAMBERT COMPANY (US) | 2007-03-13 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7179794-B2 | Multivalent macrolide antibiotics | THERAVANCE, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7173039-B2 | Protein kinase inhibitors | THERAVANCE, INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-7138542-B2 | Method of treating tinnitus | WARNER LAMBERT COMPANY (US) | 2006-11-21 | — | — | US | disclosed |
| US-20060100281-A1 | Method of treating tinnitus | DOOLEY DAVID J | 2006-05-11 | — | — | US | disclosed |
| US-7026505-B2 | Method of treating tinnitus | WARNER-LAMBERT COMPANY (US) | 2006-04-11 | — | — | US | disclosed |
| EP-1357910-B1 | METHOD FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | WARNER LAMBERT CO (US) | 2005-04-27 | — | — | EP | disclosed |
| EP-1226110-B1 | BICYCLIC AMINO ACIDS AS PHARMACEUTICAL AGENTS | WARNER LAMBERT CO (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1514541-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | Warner-Lambert Company LLC (US) | 2005-03-16 | — | — | EP | disclosed |
| EP-1506955-A1 | Bicyclic amino acids as pharmaceuticals agents | Warner-Lambert Company LLC (US) | 2005-02-16 | — | — | EP | disclosed |
| US-20040266876-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | CHOVET MARIA (FR) | 2004-12-30 | — | — | US | disclosed |
| US-6835751-B2 | Bicyclic amino acids as pharmaceutical agents | WARNER-DAMBERT COMPANY LLC | 2004-12-28 | — | — | US | disclosed |
| CN-2651997-Y | Microairgap overvoltage protector | KANGMUXUN ELECTROMAGNETIC PROT (CN) | 2004-10-27 | — | — | CN | disclosed |
| US-6784208-B2 | BICYCLIC FUSED HYDROCARBON RINGS SUBSTITUTED WITH AMINOMETHYL AND CARBOXYMETHYL GROUPS ON SAME POSITION OF RING; 3-AMINOMETHYL-BICYCLO(3.2.0)HEPTANE-3-ACETIC ACID FOR EXAMPLE | WARNER-LAMBERT COMPANY | 2004-08-31 | — | — | US | disclosed |
| US-6780403-B1 | DEODORANT INCLUDING ORGANIC DIBASIC ACID AND/OR ALKALI METAL, AMMONIUM, ZINC OR ALUMINUM SALT; ACID HAS DIFFERENCE BETWEEN FIRST AND SECOND ACID DISSOCIATION INDICES OF 1.7 OR MORE AT 25 DEGREES C. AND SECOND DISSOCIATION INDEX IS FROM 6 TO 8 | KAO CORPORATION (JP) | 2004-08-24 | — | — | US | disclosed |
| US-20040152779-A1 | Bicyclic amino acids as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2004-08-05 | — | — | US | disclosed |
| US-20040097405-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2004-05-20 | — | — | US | disclosed |
| US-6689906-B1 | Bicyclic amino acids as pharmaceutical agents | WARNER-LAMBERT COMPANY | 2004-02-10 | — | — | US | disclosed |
| EP-1357910-A2 | METHOD FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | Warner-Lambert Company LLC (US) | 2003-11-05 | — | — | EP | disclosed |
| CN-2578031-Y | Thin alloy hacksaw sheet | ZHOU JINGHU (CN) | 2003-10-08 | — | — | CN | disclosed |
| US-20030176504-A1 | Method of treating tinnitus | DOOLEY DAVID JAMES (US) | 2003-09-18 | — | — | US | disclosed |
| US-6620829-B2 | Administering a therapeutically effective amount of a GABA analog having characteristic of being an inhibitor of cartilage damage, or a pharmaceutically acceptable salt | WARNER-LAMBERT COMPANY | 2003-09-16 | — | — | US | disclosed |
| US-20030083520-A1 | Process for preparing bicyclic amino acid | PFIZER INC. | 2003-05-01 | — | — | US | disclosed |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY | 2002-10-31 | — | — | US | disclosed |
| US-6429270-B2 | HIGH ACTIVITY COORDINATION CATALYST OF MAGNESIUM AND TITANIUM, A POLYCARBOXYLIC ACID ESTER, ACID HALIDE ANDORGANOALUMINUM AND ORGANOSILICON COMPOUNDS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION | 2002-08-06 | — | — | US | disclosed |
| WO-2002058680-A2 | USE OF BICYLIC AMINO ACIDS FOR PREVENTING AND TREATING VISCERAL PAIN AND GASTROINTESTINAL DISORDERS | WARNER-LAMBERT COMPANY LLC (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-1226820-A1 | Use of bicyclic amino acids for preventing and treating visceral pain and gastrointestinal disorders | WARNER-LAMBERT COMPANY (US) | 2002-07-31 | — | — | EP | disclosed |
| US-20020072533-A1 | Method of treating cartilage damage | SCHRIER DENIS (US) | 2002-06-13 | — | — | US | disclosed |
| EP-1199072-A2 | Method of treating cartilage damage | WARNER-LAMBERT COMPANY (US) | 2002-04-24 | — | — | EP | disclosed |
| US-6376539-B1 | ANTIISCHEMIC AGENTS, CENTRAL NERVOUS SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-1197204-A1 | DEODORANTS | Kao Corporation (JP) | 2002-04-17 | — | — | EP | disclosed |
| US-20010051697-A1 | Off-line preactivated catalysts and prepolymerized catalysts | MORSE DAVID BELL (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1115754-A1 | OFF-LINE PREACTIVATED CATALYSTS AND PREPOLYMERIZED CATALYSTS | UNION CARBIDE CHEMICALS AND PLASTICS COMPANY, INC. (US) | 2001-07-18 | — | — | EP | disclosed |
| WO-2000015673-A1 | OFF-LINE PREACTIVATED CATALYSTS AND PREPOLYMERIZED CATALYSTS | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 2000-03-23 | — | — | WO | disclosed |
| US-H1722-H | POLYMERIZING PROPYLENE AND OPTIONALLY COMONOMER IN PRESENCE OF TITANIUM, MAGNESIUM, HALOGEN AND INSIDE ELECTRON DONAR CATALYST WITH ORGANOALUMINUM COCATALYST, COPOLYMERIZING PRODUT WITH ANOTHER MONOMER IN PRESENCE OF TETRAETHOXYSILANE | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY LLC | 1998-04-07 | — | — | US | disclosed |
| EP-0543264-B1 | Rewritable thermosensitive recording medium | TOPPAN PRINTING CO LTD (JP) | 1995-05-03 | — | — | EP | disclosed |
| EP-0543264-A1 | Rewritable thermosensitive recording medium | Toppan Printing Co., Ltd. (JP) | 1993-05-26 | — | — | EP | disclosed |
| EP-0291958-B1 | PROCESS FOR PRODUCING STEREOREGULAR POLYMERS HAVING A NARROW MOLECULAR WEIGHT DISTRIBUTION | UNION CARBIDE CORPORATION (US) | 1993-04-14 | — | — | EP | disclosed |
| US-5093415-A | Coordination catalyst, organoaluminum cocatalyst and electron donor having silicon-oxygen-carbon linkage; polymerization of propylene | UNION CARBIDE CHEMICALS & PLASTICS TECHNOLOGY CORPORATION (US) | 1992-03-03 | — | — | US | disclosed |
| US-4642315-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1987-02-10 | — | — | US | disclosed |
| US-4587234-A | HYPOTENSIVES | E. R. SQUIBB & SONS, INC. (US) | 1986-05-06 | — | — | US | disclosed |
| US-4499079-A | ENZYME INHIBITORS, HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1985-02-12 | — | — | US | disclosed |
| US-4147661-A | PHOSPHORUS/VANADIUM MIXED OXIDE, PROMOTER | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-04-03 | — | — | US | disclosed |
| US-4147661-A | PHOSPHORUS/VANADIUM MIXED OXIDE, PROMOTER | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1979-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (29 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289662-A1 | A PHARMACEUTICAL CO-CRYSTAL AND USE THEREOF | CCR5, SLC16A1, CCR1 | GABRR1 3150/4885SLC1A2 687/4885SLC1A1 347/4885 |
| US-20070196859-A1 | Novel antibacterial agents | ENGASE, PEPD, PGLS | GABRR1 4076/4885SLC1A2 3529/4885SLC1A1 2802/4885 |
| US-20130040971-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE2A | GABRR1 948/4885SLC1A2 1465/4885SLC1A1 1581/4885 |
| US-10751318-B2 | Pharmaceutical co-crystal and use thereof | CA13, CA12, CA14 | GABRR1 3296/4885SLC1A2 798/4885SLC1A1 430/4885 |
| US-20030176504-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRA1D | GABRR1 211/4885SLC1A2 281/4885SLC1A1 635/4885 |
| US-20070134729-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | GABRR1 4202/4885SLC1A2 3465/4885SLC1A1 2847/4885 |
| US-20130231275-A1 | AMINIOTHIAZOLES AND THEIR USES | ABAT, AADAT, AADAC | GABRR1 3179/4885SLC1A2 987/4885SLC1A1 745/4885 |
| US-20020072533-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | GABRR1 11/4885SLC1A2 241/4885SLC1A1 146/4885 |
| US-20130040955-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE6A | GABRR1 222/4885SLC1A2 1395/4885SLC1A1 1528/4885 |
| US-20190177393-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | INSR, GPR119, IRS1 | GABRR1 599/4885SLC1A2 2454/4885SLC1A1 2200/4885 |
| US-20060100281-A1 | Method of treating tinnitus | ADRA2A, ADRA1A, ADRB2 | GABRR1 272/4885SLC1A2 247/4885SLC1A1 597/4885 |
| US-20170015704-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, BCAT2 | GABRR1 2763/4885SLC1A2 263/4885SLC1A1 267/4885 |
| US-11685757-B2 | Pharmaceutical co-crystal composition and use thereof | CXCR3, CCR3, CCR5 | GABRR1 4159/4885SLC1A2 2654/4885SLC1A1 1636/4885 |
| US-20020161047-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | ALPI, VIP, SLC10A2 | GABRR1 2172/4885SLC1A2 232/4885SLC1A1 156/4885 |
| US-10428099-B2 | Pharmaceutical co-crystal composition and use thereof | CXCR3, CCR5, CCR3 | GABRR1 4079/4885SLC1A2 2685/4885SLC1A1 1599/4885 |
| US-20180186822-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | CXCR3, CCR3, CCR5 | GABRR1 4159/4885SLC1A2 2654/4885SLC1A1 1636/4885 |
| US-20120202829-A1 | 6-Cycloalkyl-pyrazolopyrimidinones for the Treatment of CNS Disorders | PDE9A, PDE7A, PDE2A | GABRR1 660/4885SLC1A2 1065/4885SLC1A1 1326/4885 |
| US-20040097405-A1 | Method of treating cartilage damage | COL2A1, COL1A1, GABRB1 | GABRR1 11/4885SLC1A2 241/4885SLC1A1 146/4885 |
| US-20140274878-A1 | AMINOTHIAZOLES AND THEIR USES | ABAT, AADAT, BCAT2 | GABRR1 2763/4885SLC1A2 263/4885SLC1A1 267/4885 |
| US-20210094979-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF | CXCR3, CCR3, CCR5 | GABRR1 4159/4885SLC1A2 2654/4885SLC1A1 1636/4885 |
| US-20090306134-A1 | Muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | GABRR1 117/4885SLC1A2 1374/4885SLC1A1 1388/4885 |
| US-20030083520-A1 | Process for preparing bicyclic amino acid | BCAT1, BCAT2, AADAT | GABRR1 584/4885SLC1A2 25/4885SLC1A1 30/4885 |
| US-20040266876-A1 | Method for preventing and treating visceral pain and gastrointestinal disorders | ALPI, VIP, SLC10A2 | GABRR1 2172/4885SLC1A2 232/4885SLC1A1 156/4885 |
| US-20040152779-A1 | Bicyclic amino acids as pharmaceutical agents | AADAT, SLC1A2, BCAT1 | GABRR1 44/4885SLC1A2 2/4885SLC1A1 7/4885 |
| US-20150025088-A1 | 6-CYCLOALKYL-PYRAZOLOPYRIMIDINONES FOR THE TREATMENT OF CNS DISORDERS | PDE9A, PDE7A, PDE2A | GABRR1 660/4885SLC1A2 1065/4885SLC1A1 1326/4885 |
| US-20080269344-A1 | Beta2-Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2B | GABRR1 100/4885SLC1A2 1366/4885SLC1A1 1734/4885 |
| US-20070179179-A1 | Beta2-adrenergic receptor agonists | ADRB2, ADRB1, ADRA2B | GABRR1 100/4885SLC1A2 1366/4885SLC1A1 1734/4885 |
| US-20070154948-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | GABRR1 4202/4885SLC1A2 3465/4885SLC1A1 2847/4885 |
| US-20090111737-A1 | Novel antibacterial agents | ENGASE, PGLS, PEPD | GABRR1 4202/4885SLC1A2 3465/4885SLC1A1 2847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.